Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

OTLK

Outlook Therapeutics Inc

Dec 12 • 04:00PM ET

1.54

Dollar change -0.03
Percentage change -1.91	%

Healthcare • Biotechnology • USA • NASD

Peers: EYPT OCUL AKBA FGEN ALDX EDIT ADMA CLSD KALA NBIX

| Held by: VTI VXF IWM VTWO IWO IWN IWC VTWG VTWV RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-10.75	Insider Own	35.60%	Shs Outstand	23.41M	Perf Week	4.76%
Market Cap	36.43M	Forward P/E	-	EPS next Y	-2.37	Insider Trans	0.06%	Shs Float	15.23M	Perf Month	-75.44%
Income	-94.05M	PEG	-	EPS next Q	-0.80	Inst Own	35.70%	Short Float	27.13%	Perf Quarter	-76.20%
Sales	0.00M	P/S	-	EPS this Y	-2.19%	Inst Trans	-2.40%	Short Ratio	2.59	Perf Half Y	-79.90%
Book/sh	-3.57	P/B	-	EPS next Y	51.65%	ROA	-205.48%	Short Interest	4.13M	Perf Year	-80.80%
Cash/sh	1.35	P/C	1.14	EPS next 5Y	-	ROE	-	52W Range	0.87 - 12.85	Perf YTD	-80.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	52.49%	ROI	-	52W High	-88.02%	Beta	0.52
Dividend TTM	-	Quick Ratio	1.07	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	77.01%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	1.07	EPS Y/Y TTM	-58.08%	Oper. Margin	-	RSI (14)	20.33	Volatility	14.02% 17.59%
Employees	24	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	29.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	45.02%	Payout	-	Rel Volume	0.42	Prev Close	1.57
Sales Surprise	-	EPS Surprise	19.64%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	1.60M	Price	1.54
SMA20	-52.78%	SMA50	-67.08%	SMA200	-77.80%	Trades		Volume	676,957	Change	-1.91%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy	$50
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy	$3
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight	$5
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral	$5 → $1
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$4.50 → $1
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight	$5
Apr-03-23	Initiated	Guggenheim	Buy	$5
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-31-22	Initiated	BTIG Research	Buy	$7
Sep-13-22	Initiated	Chardan Capital Markets	Buy	$10
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$9
May-16-19	Initiated	Oppenheimer	Outperform	$12
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

Show Previous Ratings

Dec-04-24 08:05AM	Outlook Therapeutics Announces NICE Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) -8.03%
Dec-03-24 04:30PM	Outlook Therapeutics Announces Executive Leadership Transition (GlobeNewswire) -11.08%
Nov-30-24 05:50AM	Outlook Therapeutics price target lowered to $9 from $50 at BTIG (TipRanks)
Nov-27-24 11:08AM	Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial (Pharmaceutical Technology) -65.24%
11:07AM	Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial (Clinical Trials Arena)
09:27AM	Loading…
09:27AM	Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? (Benzinga)
06:50AM	Outlook Therapeutics Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial (GlobeNewswire)
Nov-06-24 08:05AM	Outlook Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Oct-17-24 09:00AM	Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-16-24 08:05AM	Outlook Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -8.35%
Sep-13-24 09:05AM	Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series (GlobeNewswire)
Sep-04-24 08:35AM	Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial (GlobeNewswire) +9.12%
Sep-03-24 08:45AM	Outlook Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -8.30%
Aug-15-24 06:20AM	Q3 2024 Outlook Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-24 07:05AM	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire) -5.29%
09:05AM	Loading…
Aug-12-24 09:05AM	Outlook Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-09-24 07:16AM	Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now? (Insider Monkey)
Aug-07-24 08:35AM	Outlook Therapeutics to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast (GlobeNewswire)
Jul-30-24 09:10AM	Outlook Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-08-24 08:35AM	Outlook Therapeutics Announces UK MHRA Marketing Authorization of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire) +7.38%
Jun-25-24 07:30AM	3 Undervalued Gems Set to Soar 1,000% by 2026 (InvestorPlace)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-12-24 10:00AM	Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series (ACCESSWIRE)
Jun-11-24 09:05AM	Outlook Therapeutics to Present at the Virtual Investor Pitch Conference (GlobeNewswire) +7.92%
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
Jun-06-24 10:30AM	Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team (ACCESSWIRE)
May-28-24 08:05AM	Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD (GlobeNewswire)
May-17-24 04:27AM	Q2 2024 Outlook Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +6.14%
May-15-24 10:53PM	OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024 (InvestorPlace)
05:00PM	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire)
11:18AM	Loading…
May-13-24 11:18AM	Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK (MT Newswires)
08:50AM	Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
May-09-24 08:45AM	Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast (GlobeNewswire)
May-02-24 09:05AM	Outlook Therapeutics to Present at the Retina World Congress 2024 (GlobeNewswire)
Apr-29-24 09:00AM	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase (GlobeNewswire) +7.95%
Apr-26-24 06:37AM	Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-15-24 04:15PM	Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million (GlobeNewswire)
12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
Mar-22-24 07:35AM	Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) +22.59%
Mar-18-24 05:10PM	Outlook Therapeutics Announces Closing of Private Placement of up to $159 Million (GlobeNewswire) -5.52%
Mar-12-24 08:05AM	Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split (GlobeNewswire) -10.57%
Mar-06-24 03:36PM	7 of the Best Speculative Stocks You Can Snag for Less Than $1 (InvestorPlace)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-14-24 05:27PM	Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments (GuruFocus.com) +5.08% +15.35%
08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update (GlobeNewswire)
Jan-31-24 08:05AM	Outlook Therapeutics Doses First Subject in NORSE EIGHT (GlobeNewswire) -6.99%
Jan-24-24 08:06AM	Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study (Zacks) -9.87%
Jan-23-24 08:00AM	Outlook Therapeutics Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010 (GlobeNewswire) +30.53%
Jan-02-24 10:18PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire) +6.08%
Dec-27-23 02:03PM	OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023 (InvestorPlace)
09:30AM	OUTLOOK SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-26-23 02:15PM	January 2. 2024 Lawsuit Deadline: Investors who lost over $200,000 with Outlook Therapeutics, Inc. (NASDAQ: OTLK) shares should contact the Shareholders Foundation (GlobeNewswire) +5.41%
Dec-22-23 08:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU (GlobeNewswire)
Dec-19-23 08:05AM	Outlook Therapeutics Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010 (GlobeNewswire) +9.73%
Dec-06-23 08:05AM	Outlook Therapeutics Announces Strategic Organizational Realignment (GlobeNewswire)
Nov-27-23 08:05AM	Outlook Therapeutics Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010 (GlobeNewswire)
06:30AM	OTLK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
Nov-15-23 02:04PM	OTLK STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Outlook Therapeutics, Inc. (Business Wire)
Nov-14-23 08:05AM	Outlook Therapeutics Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe (GlobeNewswire) +8.83%
Nov-09-23 08:52AM	12 Best Day Trading Stocks To Buy (Insider Monkey) -11.00%
Nov-02-23 08:05AM	Outlook Therapeutics Provides Update on Type A Meetings with FDA (GlobeNewswire) -46.24%
Nov-01-23 08:05AM	Outlook Therapeutics to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference (GlobeNewswire) +5.40%
Oct-17-23 05:22PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire) +14.51% +18.85%
Oct-11-23 05:49PM	Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire) +7.84%
Sep-29-23 08:05AM	Outlook Therapeutics Requests Type A Meeting With FDA (GlobeNewswire)
Sep-21-23 08:05AM	Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks) -15.08%
Aug-30-23 06:11AM	US FDA declines to approve Outlook Therapeutics' eye disease drug (Reuters) -80.96%
06:00AM	Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD (GlobeNewswire)
Aug-28-23 11:47AM	Outlook Therapeutics (OTLK): A Deep Dive into its Overvalued Status (GuruFocus.com) +10.34%
Aug-14-23 09:55AM	Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings? (Zacks)
08:05AM	Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones (GlobeNewswire)
Aug-01-23 08:45AM	Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-11-23 08:45AM	When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit? (Simply Wall St.)
Jun-06-23 01:59PM	Why Shares of Outlook Therapeutics Rose Tuesday (Motley Fool)
May-15-23 08:05AM	Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Apr-27-23 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-10-23 11:43AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 37% stake, while 27% is held by private equity firms (Simply Wall St.)
Mar-13-23 07:00AM	Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank (GlobeNewswire)
Feb-14-23 08:05AM	Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update (GlobeNewswire)
Feb-07-23 08:05AM	Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-19-23 08:05AM	Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence (GlobeNewswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-09-23 08:05AM	Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire)
Jan-02-23 07:31AM	Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
Dec-29-22 09:05AM	Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update (GlobeNewswire) +5.94%
Dec-23-22 09:00AM	Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note (GlobeNewswire) +21.81%
06:00AM	Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-22-22 08:05AM	Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire)
Dec-01-22 08:05AM	Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference (GlobeNewswire)
Nov-22-22 08:05AM	Outlook Therapeutics® to Present at the BTIG Ophthalmology Day (GlobeNewswire)
Nov-01-22 09:55AM	Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 38% stake, while 25% is held by private equity firms (Simply Wall St.)
Oct-28-22 08:05AM	Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD (GlobeNewswire) -9.47%
Oct-05-22 06:09AM	Independent Director Kurt Hilzinger Just Bought 33% More Shares In Outlook Therapeutics, Inc. (NASDAQ:OTLK) (Simply Wall St.)
Sep-27-22 08:05AM	Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD (GlobeNewswire)
Sep-26-22 08:35AM	Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022 (GlobeNewswire)
Sep-07-22 08:05AM	Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-30-22 09:39AM	Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate (Benzinga)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KENYON LAWRENCE A	Chief Financial Officer	Sep 26 '24	Buy	5.69	5,000	28,446	5,946	Sep 30 04:53 PM
Haddadin Yezan Munther	Director	Mar 28 '24	Buy	11.82	1,882	22,242	5,049	Mar 29 10:39 AM
Evanson Jeff	CHIEF COMMERCIAL OFFICER	Mar 07 '24	Buy	0.42	62,484	26,243	808,459	Mar 11 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OTLK

Outlook Therapeutics Inc

Upgrade your FINVIZ experience